Therapeutic use of cannabinoids in neurology;Therapeutischer Einsatz von Cannabinoiden bei neurologischen Erkrankungen

Schmerz

Volumn 17, Issue 5, 2003, Pages 367-373

  Schwenkreis, P ^a   Tegenthoff, M ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Cannabinoids; Epilepsy; Multiple sclerosis; Neuroprotection; Spasticity

Indexed keywords

CANNABIDIOL; CANNABINOID DERIVATIVE; CANNABIS; DRONABINOL; PLACEBO;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG USE; DYSTONIA; EPILEPSY; GILLES DE LA TOURETTE SYNDROME; HEAD INJURY; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROPROTECTION; PARKINSON DISEASE; REVIEW; SPASTICITY; TREATMENT INDICATION;

ANALGESICS; CANNABINOIDS; CANNABIS; CLINICAL TRIALS; HUMANS; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; PAIN; PARKINSONIAN DISORDERS; PHYTOTHERAPY;

EID: 0141869081     PISSN: 0932433X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00482-003-0240-z     Document Type: Review

References (61)

1. Achiron A, Miron S, Lavie V, Margalit R, Biegon A (2000) Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J Neuroimmunol 102:26-31
2. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404:84-87
3. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V (2001) Endocannabinoids control spasticity in a multiple sclerosis model. Faseb J 15:300-302
4. Belayev L, Bar-Joseph A, Adamchik J, Biegon A (1995) HU-211, a nonpsychotropic cannabinoid, improves neurological signs and reduces brain damage after severe forebrain ischemia in rats. Mol Chem Neuropathol 25:19-33
5. Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y (1996) The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 34:446-452
6. Clifford DB (1983) Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 13:669-671
7. Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K (1991) Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 40:701-708
8. Consroe P, Musty R, Rein J, Tillery W, Pertwee R (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38:44-48
9. Consroe P, Sandyk R (1992) Potential role of cannabinoids for therapy of neurological disorders. In: Murphy L, Bartke A (eds) Marijuana/cannabinoids: neurobiology and neurophysiology. CRC Press, Ann Arbor, MI, pp 4S9-524
10. Consroe P, Sandyk R, Snider SR (1986) Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30:277-282
11. Consroe PF, Wood GC, Buchsbaum H (1975) Anticonvulsant nature of marihuana smoking. JAMA 234:306-307
12. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21:175-185
13. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949
14. Dunn M, Davis R (1974) The perceived effects of marijuana on spinal cord injured males. Paraplegia 12:175
15. Ellison JM, Gelwan E, Ogletree J (1990) Complex partial seizure symptoms affected by marijuana abuse. J Clin Psychiatry 51:439-440
16. Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, Kloog Y, Sokolovsky M (1989) Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc Natl Acad Sci U S A 86:9584-9587
17. Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM (2002) Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17:145-149
18. Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646-1647
19. Glass M, Brotchie JM, Maneuf YP (1997) Modulation of neurotransmission by cannabinoids in the basal ganglia. Eur J Neurosci 9:199-203
20. Gordon E, Devinsky O (2001) Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 42:1266-1272
21. Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF (1994) Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 55:324-328
22. Hanus L, Gopher A, Almog S, Mechoulam R (1993) Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 36:3032-3034
23. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87:1932-1936
24. Karler R, Calder LD, Turkanis SA (1986) Prolonged CNS hyperexcitability in mice after a single exposure to delta-9-tetrahydrocannabinol. Neuropharmacology 25:441-446
25. Keeler MH, Reifler CB (1967) Grand mal convulsions subsequent to marijuana use. Case report. Dis Nerv Syst 28:474-475
26. Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH (2002) Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 58:1404-1407
27. Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH, Biegon A (2002) Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med 30:548-554
28. Kogel RW, Johnson PB, Chintam R, Robinson CJ, Nemchausky BA (1995) Treatment of spasticity in spinal cord injury with dronabinol, a tetrahydrocannabinol derivative. Am J Ther 2:799-805
29. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
30. Leker RR, Shohami E, Abramsky O, Ovadia H (1999) Dexanabinol, a novel neuroprotective drug in experimental focal cerebral ischemia. J Neurol Sci 162:114-119
31. Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB (1989) Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 23:73-81
32. Mailleux P, Parmentier M, Vanderhaeghen JJ (1992) Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides. Neurosci Lett 143:200-204
33. Maneuf YP, Nash JE, Crossman AR, Brotchie JM (1996) Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol 308:161-164
34. Martyn CN, Illis LS, Thom J (1995) Nabilone in the treatment of multiple sclerosis. Lancet 345:579
35. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564
36. Maurer M, Henn V, Dittrich A, Hofmann A (1990) Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci 240:1-4
37. Mechoulam R, Hanu L (2001) The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res Manag 6:67-73
38. Meinck HM, Schonle PW, Conrad B (1989) Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 236:120-122
39. Müller-Vahl KR, Koblenz A, Jobges M, Kolbe H, Emrich HM, Schneider U (2001) Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. Pharmacopsychiatry 34:19-24
40. Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM (1998) Cannabinoids: possible role in pathophysiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand 98:502-506
41. Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM (1999) Cannabis in movement disorders. Forsch Komplementarmed 6 [suppl 3]:23-27
42. Müller-Vahl KR, Schneider U, Emrich HM (1999) Nabilone increases choreatic movements in Huntington's disease. Mov Disord 14:1038-1040
43. Müller-Vahl KR, Schneider U, Koblenz A, Jobges M, Kolbe H, Daldrup T, Emrich HM (2002) Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35:57-61
44. Müller-Vahl KR, Schneider U, Kolbe H, Emrich HM (1999) Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 156:495
45. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65
46. Nadler V, Biegon A, Beit-Yannai E, Adamchik J, Shohami E (1995) 45Ca accumulation in rat brain after closed head injury; attenuation by the novel neuroprotective agent HU-211. Brain Res 685:1-11
47. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19:2987-2995
48. Ng SK, Brust JC, Hauser WA, Susser M (1990) Illicit drug use and the risk of new-onset seizures. Am J Epidemiol 132:47-57
49. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413:527-531
50. Pertwee RG (1988) The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 36:189-261
51. Petro DJ (1980) Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 21:81,85
52. Petro DJ, Ellenberger C jr (1981) Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 21:413S-416S
53. Rodriguez de Fonseca F, Del Arco I, Martin-Calderon JL, Gorriti MA, Navarro M (1998) Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 5:483-501
54. Sandyk R, Snider SR, Consroe P, Elias SM (1986) Cannabidiol in dystonic movement disorders. Psychiatry Res 18:291
55. Schon F, Hart PE, Hodgson TL, Pambakian AL, Ruprah M, Williamson EM, Kennard C (1999) Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology 53:2209-2210
56. Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T (1997) Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol 72:169-177
57. Shohami E, Novikov M, Mechoulam R (1993) A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. J Neurotrauma 10:109-119
58. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57:2108-2111
59. Snider S, Consroe P (1984) Treatment of Meige's syndrome with cannabidiol. Neurology 34 [suppl]:147
60. Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW (1987) Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 7:39-50
61. Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T (1994) Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 28:209-214